<!doctype html><html lang=en data-theme=light><head><meta charset=UTF-8><meta name=viewport content="width=device-width,initial-scale=1"><title>Kamada Ltd. Reports Strong Q1 2025 Growth with Revenue Up 17% and Adjusted EBITDA Surging 54% - Building Texas Show News</title><meta name=description content="Kamada Ltd. reports 17% revenue growth in Q1 2025, driven by its diverse biopharmaceutical portfolio and strategic expansions, including a new plasma center."><meta name=keywords content="news,breaking news,current events,analysis,journalism"><meta name=author content="Building Texas Show"><meta property="og:title" content="Kamada Ltd. Reports Strong Q1 2025 Growth with Revenue Up 17% and Adjusted EBITDA Surging 54% - Building Texas Show News"><meta property="og:description" content="Kamada Ltd. reports 17% revenue growth in Q1 2025, driven by its diverse biopharmaceutical portfolio and strategic expansions, including a new plasma center."><meta property="og:type" content="article"><meta property="og:url" content="https://example.org/posts/2025-06-18-kamada-ltd-reports-strong-q1-2025-growth-with-revenue-up-17-and-adjusted-ebitda-surging-54/"><meta property="og:image" content="https://cdn.newsramp.app/banners/business-corporate-1.jpg"><meta name=twitter:card content="summary_large_image"><meta name=twitter:title content="Kamada Ltd. Reports Strong Q1 2025 Growth with Revenue Up 17% and Adjusted EBITDA Surging 54% - Building Texas Show News"><meta name=twitter:description content="Kamada Ltd. reports 17% revenue growth in Q1 2025, driven by its diverse biopharmaceutical portfolio and strategic expansions, including a new plasma center."><link rel=canonical href=https://example.org/posts/2025-06-18-kamada-ltd-reports-strong-q1-2025-growth-with-revenue-up-17-and-adjusted-ebitda-surging-54/><link href=https://cdn.jsdelivr.net/npm/daisyui@4.12.10/dist/full.min.css rel=stylesheet type=text/css><script src=https://cdn.tailwindcss.com></script><style>@import 'https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap';:root{--primary:#0f766e;--primary-content:#ffffff;--secondary:#64748b;--accent:#dc2626;--neutral:#0f766e;--base-100:#ffffff;--base-200:#f8fafc;--base-300:#e2e8f0;--base-content:#1f2937;--teal-600:#0d9488;--teal-700:#0f766e;--teal-800:#115e59}[data-theme=light]{--primary:#0f766e;--primary-content:#ffffff;--secondary:#64748b;--accent:#dc2626;--neutral:#0f766e;--base-100:#ffffff;--base-200:#f8fafc;--base-300:#e2e8f0;--base-content:#1f2937;background-color:#fff;color:#1f2937}html,body{font-family:inter,-apple-system,BlinkMacSystemFont,segoe ui,Roboto,sans-serif;background-color:inherit;color:inherit;line-height:1.6}main{background-color:#a5f3fc;color:#1f2937;min-height:calc(100vh - 200px)}.content-card{background:rgba(255,255,255,.95);color:#1f2937;border-radius:8px;box-shadow:0 4px 6px -1px rgba(0,0,0,.1)}h1,h2,h3,h4,h5,h6{font-weight:600;line-height:1.3}.btn-primary{background-color:#0f766e;border-color:#0f766e;color:#fff}.btn-primary:hover{background-color:#0d9488;border-color:#0d9488}a{color:#0f766e;text-decoration:none}a:hover{color:#0d9488}.nav-hover:hover{background-color:var(--primary) !important;color:var(--primary-content) !important}.dropdown-content{background-color:var(--base-100) !important;border:1px solid var(--base-300) !important}.dropdown-item:hover{background-color:var(--primary) !important;color:var(--primary-content) !important}.group:hover .group-hover\:block{display:block !important}</style></head><body class="min-h-screen bg-base-100"><div class="bg-white border-b border-gray-200"><div class="container mx-auto px-4 py-4"><div class="flex items-center justify-between"><a href=/ class="flex items-center"><img src=https://newswriter.ai/logo.svg alt=Newswriter.ai class="h-8 w-auto"></a><div class=relative><div class="dropdown dropdown-end"><div tabindex=0 role=button class="btn btn-primary">Write My Press Release
<svg class="w-4 h-4 ml-1" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"/></svg></div><ul tabindex=0 class="dropdown-content menu bg-base-100 rounded-box z-[1] w-52 p-2 shadow"><li><a href=https://newswriter.ai class=text-sm>Write New Press Release</a></li></ul></div></div></div></div></div><main><div class="container mx-auto px-4 py-8"><div class="max-w-4xl mx-auto"><div class="text-sm mb-6"><a href=/ class="text-primary hover:underline">Home</a>
<span class="text-gray-500 mx-2">/ </span><span class=text-gray-500>Article</span></div><div class=mb-8><h1 class="text-4xl md:text-5xl font-bold text-base-content leading-tight mb-6">Kamada Ltd. Reports Strong Q1 2025 Growth with Revenue Up 17% and Adjusted EBITDA Surging 54%</h1><div class="border-b border-gray-200 pb-6 mb-8"><div class="flex items-center text-sm mb-4"><span class="text-primary font-semibold">Building Texas Show News </span><span class="text-gray-400 mx-2">• </span><span class="text-base-content opacity-70">June 18, 2025</span></div><a href=https://www.newmediawire.com/news/kamada-q1-results-double-digit-growth-company-reiterates-guidance-as-it-hits-multiple-milestones-including-plasma-business-expansion-7080877 target=_blank class="inline-flex items-center text-primary hover:text-primary-focus underline font-medium">Read Original Article →</a></div></div><div class=mb-8><img src=https://cdn.newsramp.app/banners/business-corporate-1.jpg alt="Kamada Ltd. Reports Strong Q1 2025 Growth with Revenue Up 17% and Adjusted EBITDA Surging 54%" class="w-full h-96 object-cover rounded-lg shadow-lg mb-8"></div><div class="bg-base-200 p-6 rounded-lg mb-8"><h2 class="text-2xl font-bold text-base-content mb-4">Summary</h2><div class="text-lg leading-relaxed mb-8 prose prose-lg max-w-none" style=color:var(--base-content)><p>Kamada Ltd. (NASDAQ: KMDA) has reported a strong first quarter in 2025, with revenue up by 17% and Adjusted EBITDA by 54% year-over-year, signaling robust growth through its diverse portfolio and operational efficiency. CEO Amir London highlighted the company's disciplined expense management and portfolio diversity as key drivers. Notably, products like GLASSIA®, KAMRAB®, and VARIZIG® have contributed significantly to this growth, catering to treatments for emphysema, rabies prevention, and varicella disease prophylaxis, respectively. Kamada also launched a post-marketing research program for CYTOGAM®, aiming to enhance CMV disease management, and expanded its plasma collection operations with a new center in San Antonio, Texas, expected to add $8-$10 million in annual revenue. The company has reiterated its 2025 guidance, projecting total revenue between $178-$182 million and adjusted EBITDA of $38-$42 million, reflecting confidence in its strategic growth pillars.</p></div></div><div class=mb-12><h2 class="text-2xl font-bold text-base-content mb-6">Full Article</h2><div class="prose prose-lg max-w-none leading-relaxed" style=color:var(--base-content)><div class=space-y-4><p class=mb-4><p>Kamada Ltd. (NASDAQ: KMDA) has announced a remarkable first quarter for 2025, with revenues increasing by 17% to $44.0 million and Adjusted EBITDA jumping 54% to $11.6 million compared to the previous year. This growth highlights the company's successful execution of both organic growth strategies and strategic initiatives, as emphasized by CEO Amir London. The surge in revenue was primarily driven by robust sales of GLASSIA® and KAMRAB® in international markets, alongside significant contributions from VARIZIG® and royalty income from GLASSIA. These products play a vital role in addressing critical health issues, including treatments for emphysema caused by severe genetic Alpha 1-antitrypsin (AAT) deficiency, rabies prevention, and post-exposure prophylaxis of varicella disease in high-risk individuals.</p><p>The company's gross margins also saw an improvement, rising to 47% from 44% the previous year, attributed to a favorable product mix. Kamada has reaffirmed its full-year guidance, projecting total revenues to be between $178 million and $182 million, with adjusted EBITDA expected to range from $38 million to $42 million. These projections reflect the company's confidence in its growth trajectory and operational efficiency.</p><p>Among the quarter's notable achievements was the initiation of a post-marketing research program for CYTOGAM®, aimed at improving CMV disease management. Additionally, Kamada expanded its plasma collection capabilities with the opening of a new center in San Antonio, Texas, which is anticipated to contribute $8 million to $10 million in annual revenue once fully operational. The company also secured a significant deal to supply KAMRAB and VARIZIG in Latin America through 2027, expected to generate approximately $25 million in revenue. Progress on the InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin therapy continues, with an interim futility analysis scheduled by the end of 2025.</p><p>Kamada's strategic focus on enhancing its product portfolio, expanding its plasma collection operations, and advancing clinical trials underscores its commitment to addressing unmet medical needs and securing a strong position in the biopharmaceutical sector. This quarter's performance not only demonstrates Kamada's financial health but also its potential to make a lasting impact on global healthcare through innovative treatments and therapies.</p></p></div></div></div><div class="bg-base-200 p-4 rounded-lg mb-8 text-sm text-gray-600"><p>Article ID: 84080</p><p>Feed Item ID: 15488</p></div><div class=text-center><a href=/ class="btn btn-outline btn-lg">← Back to Home</a></div></div></div></main><footer class="bg-teal-700 text-white"><div class="container mx-auto px-4 py-6"><div class="flex flex-col md:flex-row justify-between items-center gap-4"><div class="flex items-center gap-4"><p class=text-sm>Newswriter.ai © 2025 All Rights Reserved</p><a href=https://newswriter.ai/privacy-policy class="text-sm hover:text-teal-200 transition-colors">Privacy Policy</a>
<a href=https://newswriter.ai/terms-of-service class="text-sm hover:text-teal-200 transition-colors">Terms of Service</a></div></div></div></footer></body></html>